THE US Food and Drug
Administration has approved
Tafinlar (dabrafenib) and Mekinist
(trametinib), for the treatment
of patients with non-resectable
melanoma.
Tafinlar is a BRAF inhibitor and
Mekinist is a MEK inhibitor, with
both approvals for patients with
particular gene mutations.
The approval comes along with a
genetic test called the THxID BRAF
test, which detects the V600E or
V600K mutation in the BRAF gene.
Melanoma is the leading cause of
death from skin disease, with about
half of melanomas arising in the
skin having a BRAF gene mutation.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jun 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jun 13
THE vaping reforms bill passed in the Senate this week has raised significant questions around pharmacy insurance premiums, business risks and regulatory compliance for community pharmacists, according to the profession’s peak body.
A COMBINATION of varenicline and nicotine lozenges may be a more effective treatment option for people looking to quit smoking compared to varenicline alone, according to results from a new clinical trial at Monash University.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.